Biopharma didn't exactly have the most wonderful Thursday going into the weekend.
Three companies - Sarepta Therapeutics, Nektar Therapeutics, and Amarin -all had to deal with some unfortunate news in the span of hours.
Sarepta stock is down 6.5% after hours. Nektar? Down more than 27%. And Amarin - a company that's enjoyed major spikes on the strength of its fish oil treatment - is down nearly 24% after hours.
Drug development is filled with failure, and luck plays a major role into the enterprise. But this trio of unfortunate developments involving manufacturing issues (Nektar), a potentially "erroneous" report from Sarepta, and the unexpected decision by the Food and Drug Administration (FDA) saying that the company's signature fish oil treatment will get, well, the FDA advisory committee treatment (something that wasn't originally expected given clinical trial data released by the company).
More on all of these issues soon. Read on for the day's news.
Can apps identify dementia? An initial study from drug maker Eli Lilly finds that the use of Apple devices like the iPhone could “differentiate people with mild Alzheimer’s disease dementia and those without symptoms” when combined with digital health apps like Beddit, Reuters reports. (Reuters)
Uber’s Stock Plunges on Growing Losses, by Danielle Abril
Northwestern Mutual CEO Hasn’t Given Up on the Stock Market, by Susie Gharib
Exclusive: McAfee Is Acquiring NanoSec, by David Z. Morris
Find past coverage. Sign up for other Fortune newsletters.